IRCT201108301475N6已完成3 期
Double blind, randomized phase 3 efficacy trial of topical nano-liposomal paromomycin in the treatment of cutaneous leishmaniasis caused by L. major
Center for Research & Training in Skin Diseases & Leprosy Tehran University of Medical Sciences; Dis0 个研究点目标入组 144 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 60 years（—）
- 性别
- All
入选标准
- •Age 12-60 years; Cutaneous leishmaniasis (CL) lesion induced by L. major; Parasitological proven cases of CL by direct smear, culture or PCR; Healthy individual otherwise of CL; onset less than 3 months; number of lesion 5 at most; ulcer size not more than 30 mm in one size; willing to participate and sign informed consent. Exclusion criteria: pregnant or lactating women; duration of lesion more than 3 months; serious illness such as heart kidney or liver diseases based on physical exam and laboratory tests; CL lesion resistant to treatment or recidivans form of lesion; number of lesions more than 5; ulcer size more than 30 mm in one direction participation in any other clinical trial in last 6 months.
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Efficacy of topical nano-liposomal Amphotericin B in the treatment of cutaneous leishmaniasis caused by L. majorCutaneous Leishmaniasis.Cutaneous leishmaniasisIRCT201510161475N10Iran Nanotechnology, Inititave concil110
尚未招募
3 期
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwaCTRI/2024/04/065558Pfizer Inc.
进行中（未招募）
1 期
To determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.EUCTR2010-021196-85-PLBavarian Nordic, Inc1,200
进行中（未招募）
1 期
To determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.EUCTR2010-021196-85-DKBavarian Nordic, Inc.1,200
进行中（未招募）
1 期
To determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate CancerMedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021196-85-NLBN ImmunoTherapeutics, Inc.1,297